A handful of antiparasitic drugs that have been around for decades — ivermectin, mebendazole, and fenbendazole — are now being tested as potential cancer treatments, and the early laboratory results have caught the attention of researchers, politicians, and desperate patients alike. At least 50 preclinical studies suggest ivermectin alone has activity against several cancer types, showing the ability to inhibit cancer cell proliferation and induce apoptosis in laboratory settings. A Phase I/II clinical trial at Cedars-Sinai Medical Center in Los Angeles is currently evaluating ivermectin combined with immune checkpoint inhibitors in metastatic triple-negative breast cancer, with results expected in October 2026. Meanwhile, mebendazole has six active or recruiting clinical trials registered on ClinicalTrials.gov, including two early-phase trials targeting glioma, a form of brain cancer.
But here is the part that gets lost in the excitement: no large-scale randomized controlled trials have confirmed therapeutic cancer benefits for any of these drugs in humans. The one completed Phase 2a study of mebendazole in advanced gastrointestinal cancer found the drug was safe and well tolerated, but no objective tumor response was observed — and some patients actually showed unusually rapid disease progression. For families dealing with cancer alongside conditions like dementia, where cognitive decline already complicates treatment decisions, understanding the difference between promising lab results and proven therapies is critical. This article covers what these drugs are and why researchers are interested in them, what the clinical trial evidence actually shows, how political momentum in states like Florida is shaping the conversation, what oncologists are worried about, and how to think about drug repurposing claims with the skepticism they deserve.
Table of Contents
- What Are These Cheap Old Drugs Being Tested Against Cancer?
- What Do the Clinical Trials Actually Show So Far?
- Florida’s $60 Million Bet on Drug Repurposing for Cancer
- Why Oncologists Are Worried About Patients Self-Treating
- The Gap Between Preclinical Promise and Clinical Proof
- What Drug Repurposing Costs Tell Us About Incentives
- Where the Research Goes From Here
- Conclusion
- Frequently Asked Questions
What Are These Cheap Old Drugs Being Tested Against Cancer?
The drugs at the center of this story belong to a class called antiparasitics, or anthelmintics — medications originally developed to treat worm infections in animals and humans. Ivermectin, which won a Nobel Prize in 2015 for its role in combating river blindness and other parasitic diseases, is widely available and costs just a few dollars per dose in its generic form. Mebendazole has been used clinically in humans for decades to treat intestinal parasites. Fenbendazole is a veterinary drug not approved for human use, though it gained a following online after a man named Joe Tippens publicly claimed it helped treat his lung cancer — a story that went viral but has never been verified in a controlled study. The concept behind testing these drugs for cancer is called drug repurposing, and it is a legitimate area of pharmaceutical research.
The idea is straightforward: drugs that have already been proven safe in humans can skip the early safety testing phase, potentially saving years and millions of dollars in development costs. Lab studies have shown that ivermectin can modulate signaling pathways involved in cancer cell growth, while mebendazole has demonstrated anticancer properties across multiple cancer types in preclinical research, according to the ecancer ReDO (Repurposing Drugs in Oncology) project. These signals are genuinely interesting to scientists. However, it is important to understand what “preclinical” means compared to “clinically proven.” Preclinical studies happen in petri dishes and animal models. Many substances kill cancer cells in a lab — bleach kills cancer cells in a lab — but that does not make them cancer treatments. The gap between showing activity against cultured cancer cells and demonstrating safe, effective treatment in a living human body is enormous, and the majority of drugs that look promising at the preclinical stage ultimately fail in human trials.
What Do the Clinical Trials Actually Show So Far?
The most important ivermectin cancer trial currently underway is the Phase I/II study at Cedars-Sinai Medical Center, which is evaluating ivermectin in combination with immune checkpoint inhibitors for metastatic triple-negative breast cancer. The trial is enrolling 34 adult participants and has an estimated completion date of October 2026. Until that data is in and analyzed, we simply do not have human evidence that ivermectin works against cancer. This is not a dismissal — it is just the current state of the science. Mebendazole is slightly further along in human testing, with six active or recruiting clinical trials including studies focused on brain cancer. But the one completed trial that has published results — a Phase 2a study in advanced gastrointestinal cancer reported in Nature Scientific Reports in 2021 — delivered sobering news.
While the drug was safe and well tolerated, researchers observed no objective tumor response. Worse, some patients experienced what appeared to be accelerated disease progression. This does not necessarily mean mebendazole caused the progression, but it is a finding that demands caution and further investigation. For fenbendazole, the picture is even less developed. The American Cancer Society has stated plainly that fenbendazole has not been tested in human studies and is intended for animal use only. Despite this, fenbendazole has developed a significant following on social media platforms, driven largely by anecdotal reports. For families caring for someone with both cancer and cognitive impairment, the risk of acting on unverified claims is compounded — a person with dementia may not be able to fully participate in weighing the risks and benefits of unproven treatments, making careful, evidence-based decision-making by caregivers all the more important.
Florida’s $60 Million Bet on Drug Repurposing for Cancer
On September 24, 2025 — World Cancer Research Day — Florida Governor Ron DeSantis and First Lady Casey DeSantis announced $60 million in funding through the Florida Cancer Innovation Fund specifically targeting research into repurposing generic drugs including ivermectin, fenbendazole, and mebendazole. The stated focus is studying these drugs’ effects on the mitochondrial-stem cell connection in cancer. The fund gives priority to 12-month clinical trials and projects serving rural and medically underserved areas in Florida, and it has already supported 95 researchers with $80 million over its first three years of existence. This is a significant investment, and it reflects a genuine public health interest. Casey DeSantis, who was diagnosed with breast cancer in 2021, has been a visible advocate for expanding cancer research options.
The fund’s emphasis on underserved communities addresses real disparities in cancer treatment access. At the same time, the 12-month trial priority raises questions among researchers about whether that timeline is realistic for generating the kind of rigorous evidence needed to change clinical practice. Cancer trials typically take years, not months, to produce meaningful results — and rushing the process risks producing data that is too preliminary to act on. The political dimension matters because it shapes patient expectations. When a governor stands at a podium and announces $60 million for ivermectin cancer research, patients and families hear something different from what scientists hear. Scientists hear “we are going to study this.” Patients — especially those who are scared and running out of options — may hear “this works.” That gap in interpretation has real consequences for treatment decisions.
Why Oncologists Are Worried About Patients Self-Treating
According to NPR reporting from March 2026, nearly half of new patients at some oncology practices have asked about ivermectin for cancer treatment. That statistic alone reveals how rapidly the conversation has shifted from laboratory curiosity to something patients are actively pursuing. Five state legislatures — Tennessee, Arkansas, Idaho, Louisiana, and Texas — have voted to make ivermectin available over the counter, further lowering the barrier to self-treatment. The core concern among oncologists is not that ivermectin is dangerous in normal doses — it has a well-established safety profile for its approved uses. The worry is substitution. Doctors fear that patients may delay or abandon proven cancer treatments like surgery, chemotherapy, radiation, or immunotherapy in favor of an unproven alternative.
Dr. John Mafi captured the statistical reality in an interview with NPR: “Most promising drugs in test tubes and mice don’t pan out in humans. That’s just a statistical reality.” This is not pessimism; it is the documented failure rate of drug development, where roughly 90 percent of drugs that enter clinical trials never reach approval. For families dealing with dementia-related cognitive decline, this situation presents an additional layer of difficulty. A person with early-stage dementia might encounter ivermectin claims on social media and become convinced it is a proven treatment, while lacking the cognitive resources to critically evaluate the evidence. Caregivers need to be prepared for these conversations and should consult with the patient’s oncologist and neurologist before making any changes to an established treatment plan.
The Gap Between Preclinical Promise and Clinical Proof
Drug repurposing is a legitimate and sometimes successful strategy — metformin, originally a diabetes drug, is being studied for cancer prevention, and thalidomide was repurposed to treat multiple myeloma. But for every success story, there are dozens of failures that never make headlines. The history of cancer research is littered with substances that showed remarkable activity in the lab and then did nothing — or caused harm — in human trials. The 50-plus preclinical studies showing ivermectin’s activity against cancer cells are a reasonable basis for further investigation, not a basis for treatment. These studies use concentrations of the drug that may not be safely achievable in the human bloodstream, test the drug against cancer cells in isolation rather than in the complex environment of a living body, and cannot account for interactions with the immune system, drug metabolism, or tumor microenvironments.
This is why the clinical trial process exists — not as a bureaucratic obstacle, but as the only reliable method we have for separating drugs that actually work from drugs that merely look like they should. One particular risk that gets little attention is the possibility that these drugs could interfere with proven treatments. The mebendazole trial in gastrointestinal cancer hinted at this possibility when some patients showed unusually rapid disease progression. While this may have been coincidental, it underscores why combining unproven drugs with standard cancer treatments outside of a clinical trial setting is genuinely dangerous. The interactions are unknown, and unknown interactions in cancer treatment can be fatal.
What Drug Repurposing Costs Tell Us About Incentives
The economics of these drugs help explain both the excitement and the research gap. Fenbendazole costs approximately $0.48 per 222mg dose. Ivermectin is widely available in generic form for a few dollars per dose. Mebendazole, interestingly, costs around $555 per 100mg pill in some markets — a reminder that “cheap” and “generic” do not always mean the same thing, and that drug pricing can vary enormously depending on the country, the formulation, and the manufacturer.
The low cost of ivermectin and fenbendazole is part of their appeal to patients, but it also creates a structural problem for research. Pharmaceutical companies have little financial incentive to fund expensive clinical trials for drugs that cannot be patented and would generate minimal profit even if proven effective. This is precisely why government funding like Florida’s Cancer Innovation Fund matters — and why some researchers have called for more public investment in repurposing studies. The science cannot advance without trials, and trials cannot happen without funding.
Where the Research Goes From Here
The next major milestone will be the results of the Cedars-Sinai ivermectin trial, expected in late 2026. If that trial shows meaningful activity against triple-negative breast cancer — one of the most aggressive and difficult-to-treat forms — it would likely trigger larger, more definitive trials. If it shows no benefit, as the mebendazole gastrointestinal cancer trial did, the scientific enthusiasm will likely cool even if the public enthusiasm does not.
What matters most right now is maintaining the distinction between hope and evidence. These drugs deserve to be studied rigorously, and the preclinical data justifies that investment. But studied rigorously is not the same as proven effective, and families facing cancer — especially those also navigating dementia and cognitive decline — deserve honest communication about where the science actually stands, not where we wish it were.
Conclusion
Ivermectin, mebendazole, and fenbendazole are real drugs with real preclinical signals suggesting anticancer activity, and they are being studied in real clinical trials. Florida has committed $60 million to this research, and the Cedars-Sinai breast cancer trial will deliver its first human results by late 2026. These are legitimate scientific developments worth following. At the same time, the one completed human trial of mebendazole in cancer showed no tumor response, no large-scale randomized controlled trials have confirmed benefits for any of these drugs, and nearly half of new oncology patients are already asking about treatments that remain unproven. For families managing both cancer and dementia, the stakes of acting on incomplete information are especially high.
Talk to your oncologist before adding anything to a treatment plan. Ask about clinical trials your loved one might be eligible for — participation in a trial is the safest way to access experimental treatments while contributing to the evidence that will help future patients. And be skeptical of anyone — online or in a state legislature — who treats laboratory findings as settled medicine. The research is underway. The answers are not in yet.
Frequently Asked Questions
Is ivermectin FDA-approved to treat cancer?
No. Ivermectin is FDA-approved for certain parasitic infections. It is being studied in one active Phase I/II clinical trial for metastatic triple-negative breast cancer at Cedars-Sinai Medical Center, but it has not been approved or proven effective for any cancer.
Can I buy fenbendazole and use it for cancer treatment?
Fenbendazole is a veterinary drug not approved for human use. The American Cancer Society notes that it has not been tested in human studies. Using veterinary medications without medical supervision carries risks including incorrect dosing and unknown drug interactions with cancer treatments.
What did Florida’s $60 million cancer research fund actually fund?
The Florida Cancer Innovation Fund, announced in September 2025, prioritizes research into repurposing generic drugs including ivermectin, fenbendazole, and mebendazole, with a focus on the mitochondrial-stem cell connection in cancer. It prioritizes 12-month clinical trials and projects serving rural and underserved communities.
Has any human trial shown these drugs work against cancer?
Not yet. The one completed Phase 2a trial of mebendazole in advanced gastrointestinal cancer found the drug was safe but showed no objective tumor response. The key ivermectin trial at Cedars-Sinai is not expected to report results until October 2026.
Should my loved one with dementia and cancer try ivermectin?
Do not make changes to any cancer treatment plan without consulting the patient’s oncologist. A person with cognitive impairment may not be able to fully evaluate treatment claims they encounter online. Caregivers should discuss any interest in experimental treatments directly with the medical team and ask about eligible clinical trials.
Why are state legislatures making ivermectin available over the counter?
Five states — Tennessee, Arkansas, Idaho, Louisiana, and Texas — have voted to make ivermectin available without a prescription. Proponents argue this increases patient access, while oncologists worry it encourages self-treatment with an unproven drug and may lead patients to delay or skip proven cancer therapies.
